SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Surrozen, Inc./DE
Date: May 21, 2025 · CIK: 0001824893 · Accession: 0000000000-25-005443

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-287434

Date
May 21, 2025
Author
Division of
Form
UPLOAD
Company
Surrozen, Inc./DE

Letter

Re: Surrozen, Inc. Registration Statement on Form S-3 Filed May 20, 2025 File No. 333-287434 Dear Craig Parker:

May 21, 2025

Craig Parker President and Chief Executive Officer Surrozen, Inc. 171 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Joshua Gorsky at 202-551-7836 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jonie I. Kondracki

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 21, 2025

Craig Parker
President and Chief Executive Officer
Surrozen, Inc.
171 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080

 Re: Surrozen, Inc.
 Registration Statement on Form S-3
 Filed May 20, 2025
 File No. 333-287434
Dear Craig Parker:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Joshua Gorsky at 202-551-7836 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Jonie I. Kondracki
</TEXT>
</DOCUMENT>